Sign inJoin waitlistJoin the waitlist

Douglas Sborov

Director of the HCI Hematology Disease Center and Plasma Cell Dyscrasias Program · Univ of Utah Sch of Med

Credentials: · · · · · · ·

History

Univ of Utah Sch of Med
Present
Univ of Utah Sch of Med
Present

Hematology and Medical Oncology
2012–2015
Internal Medicine
University of Utah School of Medicine
2009–2012
The Ohio State University
2005–2009
University of Wisconsin-Madison

Research

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology · 2020 · 657 citations
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Blood · 2020 · 617 citations
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
Journal of Clinical Oncology · 2023 · 271 citations

Larry Anderson
38 papers
DH
Doris Hansen
30 papers
Peter Voorhees
30 papers
Ghulam Mohyuddin
27 papers · 15 as a resident
Jack Khouri
27 papers
LS
Leyla Shune
27 papers
Krina Patel
25 papers
Surbhi Sidana
25 papers
Danai Dima
23 papers · 8 as a fellow
Aimaz Afrough
21 papers
Christopher Ferreri
21 papers · 8 as a fellow
Craig Hofmeister
21 papers

Grants

Curing Through Cooperation: Aligning Cooperative Groups to Investigate Novel Therapeutic Approaches to Cure Plasma Cell Dyscrasias
National Cancer Institute · R50
Contact PI · $173.8K · Utah State Higher Education System--University of Utah
2026–2031

Clinical trials

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2027–2032
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Principal investigator · Recruiting
University of Utah
2025–2029
Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Principal investigator · Terminated · Phase 1
University of Utah
2021–2022
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Site PI · Recruiting · Phase 1
Caribou Biosciences, Inc.
2023–2027